Over the past several months 4SC has reported progress with both its clinical-stage assets – resminostat and 4SC-202. The pivotal trial with resminostat as a maintenance therapy in advanced CTCL passed the first DSMB review and is on track to report data in H119. The Phase Ib/II study with 4SC-202 for melanoma has been initiated, while another Phase II study with 4SC-202 for GI cancer should start in Q118. 4SC-208 completes the core portfolio and is expected to enter the clinic in early
09 Feb 2018
Steady R&D newsflow
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Steady R&D newsflow
4SC AG (VSC:FRA) | 0 0 4.2% | Mkt Cap: 249.2m
- Published:
09 Feb 2018 -
Author:
Dr Jonas Peciulis -
Pages:
4
Over the past several months 4SC has reported progress with both its clinical-stage assets – resminostat and 4SC-202. The pivotal trial with resminostat as a maintenance therapy in advanced CTCL passed the first DSMB review and is on track to report data in H119. The Phase Ib/II study with 4SC-202 for melanoma has been initiated, while another Phase II study with 4SC-202 for GI cancer should start in Q118. 4SC-208 completes the core portfolio and is expected to enter the clinic in early